Taking into account all relevant factors, OPKO Health, Inc. (NASDAQ:OPK) scores 72% Sell on the technical side. The share price is also flashing a Sell from the Barchart TrendSpotter trading system. Investors starting out on a short-term path of investing should know that short terms indicators for OPK averaged 50% Sell with an average daily trading volume over the past 20 days at 4230015 shares. Those using medium-term investment strategies, the shares have overall a 0.5% Sell signal while the 50-day average daily volume remained almost 4482466 shares. It’s also important to note that the stock, whose average daily volume over the 100 days as of this piece was 4726230 shares, is signaling100% Sell for long term investors.
The stock is lingering around the initial support level of $1.51. After this, the following support is at the zone of $1.46. Up until the time the OPK stock hit levels beyond the current one, bulls should have no alarm. In terms of its momentum, the stock’s RSI hit 58.43 on the daily chart, and this may be a cause for concern. In case the price goes below $1.46 level on closing basis, there may be more profit booking with the stock growing weaker. Still, getting to the $1.59 level may cause a pull-back move approaching $1.62 mark.
OPKO Health, Inc. (OPK) is most likely going to rise 163.06 percent in the coming 12 months, as per price target approximations compiled by finviz. Nevertheless, they have set the price target at a $6 as 12-month high price target. This represents a whopping 282.17 percent increase from the current trading price of shares. The 52-week median price target given by the analysts is $4, which means a return possibility of 154.78 percent in comparison with the closing price of the stock of $1.57 in recent trading session. The lowest price set for the stock is $2.5 which is just above 59.24 percent from OPK share’s price at the end of session.
Let’s take a glimpse at some insider activity at OPKO Health, Inc. (NASDAQ:OPK) and observe the pattern. The earliest insider trade happened on 01/13/2020. FROST PHILLIP MD ET AL gathered a total of 50 thousand shares of the firm at average share price of $1.44. The total amount for the purchase was set at $72 thousand. On completing this exchange, the CEO & Chairman, 10% Owner account balance was 222 million shares. The stock grew 9.72 percent from that insider purchase. On 01/10/2020, FROST PHILLIP MD ET AL, CEO & Chairman, 10% Owner, did a purchase of 50 thousand shares at a price of $1.48 per share. This increased 74 thousand shares to the insider’s fortune and the stock experienced a 6.76 percent rally in price since the news became public. This exchange saw 222 million shares get into the CEO & Chairman, 10% Owner account. On 01/08/2020, CEO & Chairman, 10% Owner FROST PHILLIP MD ET AL recorded a purchase transaction valued at $73.5 thousand. The purchase at $1.47 a share has added 50 thousand shares into the insider’s portfolio position. Meanwhile, shares price witnessed 7.48 percent increase since the transaction reporting date. The company insider is left with 222 million shares remaining in the account. FROST PHILLIP MD ET AL, who works as CEO & Chairman, 10% Owner at the company, performed a purchase of 100 thousand shares in a transaction worth $146 thousand. The acquisition recorded on 12/30/2019 was priced at $1.46 per share. The stock price soared 8.22 percent since the transaction. FROST PHILLIP MD ET AL currently holds a stake of 222 million in OPK stock which is worth $348.54 million after the insider buying.
In the recent trading session, OPKO Health, Inc. (NASDAQ:OPK) shares gained 0.97% or 0.02 points to reach at $1.57 with a thin trading volume of 667.064 thousand shares. It opened the trading session at $1.5, the shares rose to $1.58 and dropped to $1.4985, the range by which the price of stock traded the whole session. The company now has a market cap of $1.05 billion and currently has 674.76 million outstanding shares. OPKO Health, Inc. (OPK) stock has plunged -0.64 percent of market value in 21 trading days.
Stock analysts at Piper Jaffray, assumed coverage of shares of OPKO Health, Inc. (NASDAQ:OPK) with Overweight recommendation, according to their opinion released on November 25. JP Morgan analysts have downgraded their rating of OPK shares from Neutral to Underweight in a separate flash note to investors on March 02. Analysts at JP Morgan downgraded the company stock to a Neutral call from its previous Overweight stance, in a flash note that dated back to September 14.
OPK stock’s trailing 3-year beta is 2.39, meaning there will be a greater rate of return, although posing a higher risk. The part of a firm’s profit given to each outstanding share of regular stock was -$0.48 share in the trailing 52 weeks. The stock’s value surged 5.44 percent year to date (YTD) compared to a decline of -58.99 percent in 52 week’s period. The firm’s shares are still trading -59.77 percent below its 1-year high of $3.89 and 17.67 percent up from 52-week low of $1.33. The average consensus ranking on the company is 1.8, on a ranging where 5 is equal to a consensus sell rating. In other words, the mean analyst recommendations are ranking this stock as a buy.
OPKO Health, Inc. (OPK) shares are trading at a P/E ratio of -3.03 times earnings posted in the trailing 12 months. The industry OPK deals with has an average P/E of 25.19. Its P/B ratio is standing at 0.54X compared to the 11.59 industry average. It is additionally sporting a 1.43 on the Price-to-Sales ratio, compared to the industry’s P/S average of 2.83. OPKO Health, Inc. has a 35.5% gross profit margin, with its operating margin around -28%. Alongside this, the company’s net profit margin currently stands at -31%.
Past records have indicated that shares in OPKO Health, Inc. declined on 21 different earnings reaction days and we have yet to see whether this trend will play out and remain in place when the company reports upcoming earnings. Investors will get the next hint of OPK’s Q4 earnings on February 25. Analysts are predicting revenue to suffer decline of -2.7 percent to $216M in the financial fourth quarter, while EPS will soar by about -30.77 percent to -$0.09 per share. In the last quarter, it’s earnings of -$0.1 per share came worse than the -$0.08667, adjusted, expected by Thomson Reuters consensus estimate. Revenue for the quarter was $221.9M, missing the $245.27M analysts had expected. Earnings are seen to rise by 50.2 percent this year, 30.2 percent in the coming year and the trend continues by 12 percent every year in the next 5 years.